- Details
- Description
Packaging Size:
1 Bottle/Box
Strength:
25mg/1ml
Composition:
Bevacizumab (贝伐珠单抗)
Treatment:
Several Types of Cancer
Form:
Injection
Brand:
Avzivi (普贝希)
Quantity Unit:
100mg/4ml/Box,400mg/16ml/Box
Manufacturer:
Bio-Thera Solutions,China
Avzivi® (Bevacizumab-tnjn) sold under the brand name POBEVCY (普贝希) in China, is a humanized monoclonal antibody that targets VEGF. It specifically binds to VEGF and blocks the binding of VEGF to its receptor, thereby reducing neovascularization, inducing the degradation of existing blood vessels, and thereby inhibiting tumor growth.
Dec 7, 2023，The FDA has approved the fifth bevacizumab biosimilar, Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) for the treatment of several types of cancer. Avzivi® (BAT1706) is Bio-Thera Solutions’ second FDA approved product in the United States. Avzivi® is the second biosimilar researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States.
